Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients

JJ Zwaginga, Ronnie van der Holt, Peter te Boekhorst, BJ Biemond, MD Levin, R van der Griend, A Brand, S Zweegman, HFM Pruijt, Viera M.J. Novotny, A Vreugdenhil, MR De Groot, O de Weerdt, E C M van Pampus, T M van Maanen-Lamme, S Wittebol, MR (Martin) Schipperus, MH Silbermann, PC Huijgens, Marleen LutenRene Hollestein, J A C Brakenhoff, JG Schrama, FAA Valster, G A Velders, H R Koene, Hovon Study Grp Dutch

Research output: Contribution to journalArticleAcademicpeer-review

16 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)E90-E92
JournalHaematologica
Volume100
Issue number3
DOIs
Publication statusPublished - 2015

Cite this